Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-PD-1 antibody-activated tumor-infiltrating lymphocytes

A preparation of autologous tumor infiltrating lymphocytes (TILs) activated by an anti-programmed cell death protein 1 (PD1) antibody, with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and ex-vivo activated in the presence of anti-PD-1 antibody. Upon infusion of the autologous anti-PD1 antibody-activated TILs back into the patient, the cells specifically target and kill the patient's tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-PD1 antibody-activated autologous TILs autologous anti-PD-1 antibody-activated TILs

autologous anti-PD-1 antibody-activated tumor-infiltrating lymphocytes

Search NCI's Drug Dictionary